Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triapine and Lutetium Lu 177 Dotatate in GEP-NETs
NCT04234568Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2020
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of triapine in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 8 weeks, Recommended Phase 2 Dose at 8 weeks and 1 more. Started Jul 2020; status: active, not recruiting.
02
Drugs
triapine
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT04234568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04234568.